Myriad Genetics (MYGN) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $6.52 +8.31%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $177.8 million versus the consensus estimate of $169.47 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Wendy's (WEN) Tops Q3 EPS by 3c
- GCI Liberty, Inc. (GLIBA) Tops Q3 EPS by 94c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
